|
|
|
|
|
|
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
100 Clinical Results associated with Ocellaris Pharma, Inc.
0 Patents (Medical) associated with Ocellaris Pharma, Inc.
100 Deals associated with Ocellaris Pharma, Inc.
100 Translational Medicine associated with Ocellaris Pharma, Inc.